Arizona Bioscience News: UA given $43M federal grant; AZ patient to receive new heart stent; Insys Therapeutics gets FDA nod

July 7, 2016

By Matt Ellsworth

UA logoBeacon Biomedical opens R&D laboratory to advance early cancer detection research / Phoenix Business Journal

Beacon Biomedical Inc., a Scottsdale-based company that develops lab and point-of-care blood tests for colon, breast, and lung cancer screenings and their early detection, will open offices and a laboratory at the Center for Entrepreneurial Innovation in Phoenix.

Tucson-based SynCardia files for Chapter 11 bankruptcy, has buyer / Arizona Daily Star

Tucson-based SynCardia Systems, maker of the only Food and Drug Administration-approved temporary artificial heart, has filed for Chapter 11 bankruptcy reorganization with plans to sell all of its assets to a Philadelphia-based private-equity firm while continuing operations without interruption.

University of Arizona receives $43.3 million for ‘bold new research effort’ / Arizona Daily Star

The National Institutes of Health is giving the University of Arizona a $43.3 million award over five years as part of the Precision Medicine Initiative to help identify new ways to treat and prevent disease.

Arizona patient to receive first FDA-approved fully dissolving heart stent / Phoenix Business Journal

A cardiologist at HonorHealth Scottsdale Shea hospital will implant the first FDA-approved fully dissolving heart stent in an Arizona patient.

My Turn: ‘Exodus’ at UA medical schools opens unique opportunity / Arizona Republic (Op-ed)

Dr. Darrell Wadas, chief of staff at Banner-University Medical Center Phoenix and a clinical assistant professor at the University of Arizona Medical School, writes that the changes at UA medical schools in Phoenix and Tucson could create something greater than this state has ever seen.

Phoenix pharma firm gets FDA nod on cannabis treatment; sends stock soaring / Phoenix Business Journal

Phoenix-based Insys Therapeutics Inc. has received approval from the FDA to begin marketing its cannabis treatment product, Syndros, to treat anorexia associated with weight loss in patients with AIDS as well as nausea and vomiting associated with cancer chemotherapy. Read also: Insys Therapeutics seeks boost from new drugs

UA to add health sciences building and a parking garage to campus with future construction projects / The Daily Wildcat

Site preparations began on the UA campus for the $165 million, 212,000-square-foot Health Sciences Innovation building that’s set to be completed by June 2018 featuring state-of-the-art simulated practice rooms where students can replicate situations in surgical and emergency rooms, as well as perform demonstrations with live patients.